This is a case series of 5 patients who were treated with the direct antithrombin agents (lepirudin or argatroban) for known or suspected heparin-induced thrombocytopenia thrombosis syndrome (HITTs). Coincidentally all had evidence of disseminated intravascular coagulation (DIC). The DIC parameters improved with treatment and each patient was successfully discharged from the hospital. These observations provide evidence that the direct antithrombin inhibitors, lepirudin and argatroban, can improve DIC. Moreover the presence of DIC in a patient with suspected HITTs should not mitigate against the use of these agents.
1. Greinacher A, Janssens U, Berg G, et al. Lepirudin [recombinant hirudin] for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study [HAT] investigators. Circulation1999;100:587-587.
2.
2. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin [lepirudin] provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation1999;99:73-73.
3.
3. Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan [argatroban] in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost1997;23:197-197.
4.
4. Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Semin Hematol1998;35:26-26.
5.
5. Hauptmann J, Bruggener E, Marwardt F. Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats. Haemostasis1987;17:321-321.
6.
6. Hermida J, Montes R, Parmo JA, Rocha E. Endotoxin-induced disseminated intravascular coagulation in rabbits: Effect of recombinant hirudin on hemostatic parameters, fibrin deposits, and mortality. J Lab Clin Med1998;131:77-77.
7.
7. Krupinski K, Breddin HK, Markward F, Haarmann W. Antithrombotic effects of three thrombin inhibitors in a rat model of laser-induced thrombosis. Haemostasis1989;19:74-74.
8.
8. Higuchi M, Kunitomi 0, Nishida Y, et al. [Effect of MD-805, a synthetic thrombin inhibitor on disseminated intravascular coagulation developing in hematological disorders]. Rinsho Ketsueki1985;26:1754-1754.
9.
9. Kumon Y, Tanaka K, Nakjima N, et al. Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation. Crit Care Med1984;12:1039-1039.
10.
10. Saito M, Asakura H, Jakaji H, et al. Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with haematological malignancy. Blood Coagul Fibrinolysis1995;6:60-60.
11.
11. Yamada K.A clinical trial of MD-805, a synthetic thrombin inhibitor, for the treatment of DIC. Bibl Haematol1983;49:343-343.